Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov;15(11):1548-1555.
doi: 10.1111/jdi.14296. Epub 2024 Aug 22.

Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial

Xiyu Liu  1 , Xiaohong Wang  1 , Mengxun Xie  1 , Lulu Cao  1
Affiliations
Randomized Controlled Trial

Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial

Xiyu Liu et al. J Diabetes Investig. 2024 Nov.

Abstract

Aims: To investigate the efficacy of the integrated data platform of cloud hospital combined with dietary management for adults with type 2 diabetes.

Materials and methods: We conducted a randomized controlled clinical trial. One hundred eighty patients with type 2 diabetes were randomly allocated into a control group (Group A) and an experimental group (Group B). Routine standard diabetes care was applied to the patients in Group A. The integrated data platform with dietary management was applied to Group B. Individualized diabetes education videos were sent to the patients through the platform. The primary endpoint was the change in HbA1c and change in body weight from baseline to Week 12 during the follow-up.

Results: At Week 12, HbA1c was 7.4 ± 0.7%, 6.9 ± 0.9% in Groups A and B, P < 0.01. The rate of fasting blood glucose <7 mmol/L, and glycosylated hemoglobin <7% was higher in Group B than in Group A. At Week 12, there was a significant weight loss and body mass index decrease in the overweight or obese patients of the experimental group. Those overweight or obese patients in the experimental group utilizing the appetite suppressant semaglutide achieved the most significant weight loss, with a 13.4% reduction after 12 weeks.

Conclusions: The integrated data platform combined with personalized diabetes education video delivery was verified to be a more effective management mode for diabetes. For overweight or obese adults with diabetes, the use of semaglutide in conjunction with dietary management and the integrated data platform led to greater weight loss.

Keywords: Dietary intervention; Digital platform; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Approval of the research protocol: This study conformed to the provisions of the Declaration of Helsinki. It was approved by the Ethics Committee of Dongyang People's Hospital.

Informed consent: All participants signed written informed consent before eligibility screening.

Registry and the registration no. of the study/trial: The approval date of registry was 30/01/2024, and the registration no. was ChiCTR2400080460.

Animal studies: N/A.

Figures

Figure 1
Figure 1
Change of HbA1c from baseline to endpoint. The control group (group A, n = 75), the experimental group (group B, n = 73). HbA1c, glycosylated hemoglobin.
Figure 2
Figure 2
The rate of subjects with HbA1c <7% and FBG <7 mmoL/L at the endpoint. The control group (group A, n = 75), the experimental group (group B, n = 73). FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin.
Figure 3
Figure 3
Change of weight and BMI in the overweight or obese patients of the experimental group. The results of the overweight or obese patients of experimental group, n = 58. BMI, body mass index.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. GBD 2021 Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 2023; 402: 203–234. - PMC - PubMed
    1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country‐level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119. - PMC - PubMed
    1. Su B, Wang Y, Dong Y, et al. Trends in diabetes mortality in urban and rural China, 1987–2019: a Joinpoint regression analysis. Front Endocrinol (Lausanne) 2022; 12: 777654. - PMC - PubMed
    1. American Diabetes Association Professional Practice Committee . 5. Facilitating behavior change and well‐being to improve health outcomes: standards of medical care in diabetes‐2022. Diabetes Care 2022; 45(Suppl 1): S60–S82. - PubMed
    1. Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev 2019; 35: e3158. - PubMed

Publication types